Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosciclopirox Window of Opportunity Study in Bladder Cancer
NCT04525131Phase 2Completed
- Sponsor
- CicloMed LLC
- Start
- Nov 2020
- Primary completion
- Dec 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fosciclopirox in bladder cancer, sponsored by CicloMed LLC. Started Nov 2020; status: completed.
02
Drugs
fosciclopirox
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT04525131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04525131.